Publication details
Nové farmakologické přístupy u hypertenze a srdečního selhání
| Title in English | New possibilities for heart failure and hypertension therapy |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Article in Proceedings |
| Conference | Arteriální hypertenze - současné klinické trendy : XI. sympozium : sborník přednášek |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | hypertension; heart failure; LCZ 696; serelaxin |
| Attached files | |
| Description | The first medicineis a dual inhibition of angiotensine II receptors (ARB) and neprilysin (NEP). It is based on the positive clinical effects of ARB and inhibition of vasoactive natriuretic peptides breakdown. The first large clinical trial of hypertension therapy showed sufficient hypotensive effect of LCZ 696 in heart failure with preserved ejection fraction. LCZ 696 significantly reduced the concentration of NT- proBNP. Another medicine is serelaxin (RLX030), the first recombinant form of the human hormone relaxin 2. Its effect has been studied in acute heart failure, Pre RELAX- AHF and RELAX- AHF trials, which demonstrated favourable hemodynamic effects and also reduction in the 180- day mortality. |